| # | Drug | Count |
|---|---|---|
| 0 | PEMBROLIZUMAB | 11106 |
| 1 | NIVOLUMAB | 9599 |
| 2 | CARBOPLATIN | 5706 |
| 3 | ENZALUTAMIDE | 5409 |
| 4 | EVEROLIMUS | 4591 |
| 5 | LETROZOLE | 4255 |
| 6 | PACLITAXEL | 3993 |
| 7 | FULVESTRANT | 3984 |
| 8 | CAPECITABINE | 3826 |
| 9 | IPILIMUMAB | 3667 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | AFATINIB | 1671 | 0.2564 |
| 1 | STREPTOZOCIN | 50 | 0.2294 |
| 2 | GEFITINIB | 1811 | 0.2030 |
| 3 | PRALATREXATE | 118 | 0.1852 |
| 4 | CERITINIB | 425 | 0.1796 |
| 5 | NECITUMUMAB | 63 | 0.1409 |
| 6 | RUCAPARIB | 1182 | 0.1355 |
| 7 | TISAGENLECLEUCEL | 587 | 0.1335 |
| 8 | RAMUCIRUMAB | 783 | 0.1303 |
| 9 | FULVESTRANT | 3984 | 0.1260 |
| # | Drug class | Count |
|---|---|---|
| 0 | Programmed Death Receptor-1 Blocking Antibody [EPC] | 21063 |
| 1 | Kinase Inhibitor [EPC] | 19699 |
| 2 | Platinum-based Drug [EPC] | 9703 |
| 3 | Corticosteroid [EPC] | 7177 |
| 4 | Nucleoside Metabolic Inhibitor [EPC] | 6859 |
| 5 | Microtubule Inhibitor [EPC] | 6334 |
| 6 | Aromatase Inhibitor [EPC] | 6105 |
| 7 | Androgen Receptor Inhibitor [EPC] | 5811 |
| 8 | mTOR Inhibitor Immunosuppressant [EPC] | 4644 |
| 9 | Alkylating Drug [EPC] | 4593 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Vascular Endothelial Growth Factor Receptor 2 Antagonist [EPC] | 783 | 0.1303 |
| 1 | Bispecific gp100 Peptide-HLA-directed CD3 T Cell Engager [EPC] | 54 | 0.1127 |
| 2 | Estrogen Receptor Antagonist [EPC] | 4114 | 0.1069 |
| 3 | Poly(ADP-Ribose) Polymerase Inhibitor [EPC] | 1959 | 0.1010 |
| 4 | Programmed Death Receptor-1 Blocking Antibody [EPC] | 21063 | 0.0935 |
| 5 | CTLA-4-directed Blocking Antibody [EPC] | 3860 | 0.0861 |
| 6 | Claudin 18.2-directed Cytolytic Antibody [EPC] | 77 | 0.0857 |
| 7 | Androgen Receptor Inhibitor [EPC] | 5811 | 0.0804 |
| 8 | Lymphocyte Activation Gene-3 Blocker [EPC] | 28 | 0.0711 |
| 9 | Programmed Death Ligand-1 Blocker [EPC] | 1439 | 0.0678 |